Disease Detail

ID DOID:3459
Name breast carcinoma
Definition A breast cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RB1 mut TP53 mut R547 breast carcinoma sensitive detail...
TP53 mutant RB1 wild-type R547 breast carcinoma sensitive detail...
TP53 wild-type RB1 wild-type R547 breast carcinoma sensitive detail...
PIK3CA E545K XL147 breast carcinoma sensitive detail...
ERBB2 positive SYD985 breast carcinoma sensitive detail...
Unknown unknown MGCD516 breast carcinoma not applicable detail...
FGFR2 pos FGFR3 pos E7090 breast carcinoma sensitive detail...
Unknown unknown CVX-241 breast carcinoma not applicable detail...
Unknown unknown RXDX-106 breast carcinoma not applicable detail...
Unknown unknown RXDX-106 + unspecified PD-1 antibody breast carcinoma not applicable detail...
TP53 mutant Camptothecin + CHIR-124 breast carcinoma predicted - sensitive detail...
TP53 inact mut CHIR-124 + Irinotecan breast carcinoma predicted - sensitive detail...
TP53 inact mut CHIR-124 + SN-38 breast carcinoma predicted - sensitive detail...
Unknown unknown MRx0518 breast carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01293032 Phase I Tamoxifen Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed
NCT01466972 Phase II Pazopanib Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Active, not recruiting
NCT01864746 Phase III Palbociclib A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B) Active, not recruiting
NCT01945775 Phase III Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA) Active, not recruiting
NCT01952054 Phase II Denosumab Denosumab for Breast Cancer With Bone Mets Completed
NCT02034916 Phase II Talazoparib A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Completed
NCT02115282 Phase III Exemestane + Goserelin Entinostat + Exemestane + Goserelin Exemestane With or Without Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting
NCT02270372 Phase I Varlilumab ONT-10 Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer Completed
NCT02278965 Phase I Metformin Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer Active, not recruiting
NCT02411656 Phase II Pembrolizumab MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC) Recruiting
NCT02436993 Phase II Bevacizumab Pertuzumab + Trastuzumab Carboplatin + Paclitaxel Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02658812 Phase II Talimogene laherparepvec Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery Recruiting
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT03004534 Phase 0 Darolutamide A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201 Completed
NCT03238196 Phase I Erdafitinib + Fulvestrant + Palbociclib Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer Recruiting
NCT03238495 Phase II Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Carboplatin + Docetaxel + Metformin + Pertuzumab + Trastuzumab Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer Recruiting
NCT03238703 FDA approved Tamoxifen Exemestane Toremifene Anastrozole Letrozole Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn
NCT03747042 Phase I Letrozole Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer Recruiting
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Recruiting
NCT03916744 Phase I GDC-9545 A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer Recruiting
NCT03962647 Phase I Letrozole A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer Not yet recruiting